Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 20, 2023Journal of Cancer Research and Clinical OncologyOpen Access

Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

TGThomas GeorgiMedical University of GrazLKLars KurchUniversity Hospital LeipzigGFGeorg‐Nikolaus FrankeLeipzig University of Applied Sciences

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Georgi et al. (2023) studied this question.

synapsesocial.com/papers/6a7c31a8d51985d5a1c29dbahttps://doi.org/10.1007/s00432-023-04587-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,746 citations
  2. 2Report on the First International Workshop on interim-PET scan in lymphoma2009 · 762 citations
  3. 3Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma2021 · 57 citations
  4. 4Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma2020 · 428 citations
  5. 5Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma2022 · 138 citations